The 3.9 monoclonal antibody specifically binds to CD11c, which is also known as Integrin alpha X (αX Integrin/ITGAX), or p150,95 Integrin alpha chain. CD11c is a ~150 kDa type I transmembrane glycoprotein. It is expressed on monocytes, macrophages, granulocytes, NK cells, dendritic cells, and subsets of B and T cells. It associates with CD18 (Integrin beta 2/β2 Integrin) to form the CD11c/CD18 complex, which is also known as p150,95 Integrin, or the Type 4 Complement Receptor (CR4). CD11c/CD18 binds fibrinogen and reportedly serves as a receptor for iC3b and ICAM-1/CD54. CD11c/CD18 functions as an adhesion molecule that mediates cellular binding to ligands expressed on stimulated epithelium and endothelium. The 3.9 monoclonal antibody crossreacts with CD11c expressed by Rhesus macaque leucocytes.
The antibody was conjugated to an oligonucleotide that contains an antibody clone-specific barcode (ABC) flanked by a poly-A tail on the 3' end and a PCR handle (PCR primer binding site) on the 5' end. The ABC for this antibody was designed to be used with other BD AbSeq oligonucleotides conjugated to other antibodies. All AbSeq ABC sequences were selected in silico to be unique from human and mouse genomes, have low predicted secondary structure, and have high Hamming distance within the BD AbSeq portfolio, to allow for sequencing error correction and unique mapping. The poly-A tail of the oligonucleotide allows the ABC to be captured by the BD Rhapsody™ system. The 5' PCR handle allows for efficient sequencing library generation for Illumina sequencing platforms.
NOTE: The BD Rhapsody Single-Cell Analysis System must be used with the BD Rhapsody Express Instrument.